siRNA, Anti-MAP2K2, 2'-MOE/LNA/Ribo/Backbone-modified(CAT#: SIRGT18613WQ-2MOE)
The product SIRGT18613WQ-2MOE is a type of small interfering RNA (siRNA) that targets MAP2K2 gene and regulates the expression of gene. The siRNA interferes with the expression of MAP2K2 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2'-O-methoxyethyl (2'-MOE) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.
| Specifications | |
|---|---|
| NCBI RefSeq | NM_030662.3 |
| Alternative Names | CFC4; MAPKK2; MEK2; MKK2; PRKMK2 |
| Related Diseases | Cardiofaciocutaneous Syndrome |
| Purification | HPLC |
| Sub Cat | Target | Species | Modification | Scale | |
|---|---|---|---|---|---|
| SIRGT19613WQ-LNA | MAP2K2 | Human | Locked Nucleic Acid (LNA) | ||
| SIRGT16613WQ-RB | MAP2K2 | Human | Ribo-modified | ||
| SIRGT17613WQ-BB | MAP2K2 | Human | Backbone-modified |